反义和RNAi治疗市场- 技术（RNA干扰、反义RNA）、给药途径（鞘内、静脉内、皮下）、应用（神经退化、癌症、皮肤、遗传性疾病） - 全球预测（2024年至2032年）

在研究和开发的不断发展以及临床试验的扩大的推动下，全球反义和 RNAi 治疗市场将于 2024 年至 2032 年以 18.2% 的复合年增长率增长。持续的研发努力导致创新疗法的发现和递送机制的改进，从而增强反义和 RNAi 治疗的功效。此外，临床试验的扩大验证了这些进步并支持它们通过监管途径的进展。正在进行的研究和强有力的试验活动的协同作用促进了市场成长，增加了这些先进治疗解决方案的可用性和采用。

例如，2023年8月，Sirnaomics Ltd.成功完成了其STP707 RNAi治疗研究的第一阶段，在治疗对先前治疗无反应的晚期癌症患者的多种实体瘤方面显示出积极的结果。这项进展凸显了 RNAi 疗法在解决其他疗法失败的复杂肿瘤病例方面的潜力，增强了基于 RNAi 的解决方案的吸引力。它可能会推动对 RNAi 疗法的投资和研究增加，扩大市场机会，并验证 RNAi 技术在癌症治疗中的有效性。

反义和 RNAi 治疗行业根据技术、给药途径、应用和地区进行划分。

受其实用性和患者友善性的推动，皮下注射细分市场到 2032 年将经历显着的改善。皮下注射允许以相对简单的技术和最小的不适来进行治疗，使其成为长期治疗的理想选择。这种给药途径也非常适合需要频繁给药或自行给药的治疗，从而提高患者的依从性。随着反义和 RNAi 疗法的进步，皮下注射的便利性和效率使其成为临床广泛使用的首选方法。

由于肿瘤学标靶治疗的需求不断增加，2024 年至 2032 年间，癌症领域将大幅成长。反义和 RNAi 技术提供了精确的机制来沉默与癌症进展相关的基因，从而提供创新的治疗方法。随着对癌症基因组学理解的进步，这些疗法对于制定个人化医疗策略变得至关重要。改善患者治疗效果和克服癌症治疗抗药性的巨大潜力推动了该领域在市场上的主导地位。

由于该国医疗保健产业的快速成长和对生物技术的投资不断增加，亚太地区反义和 RNAi 治疗市场份额从 2024 年到 2032 年将出现显着的复合年增长率。该地区不断扩大的患者群体、慢性病盛行率的上升以及政府的支持性政策推动了对先进治疗解决方案的需求。此外，大量的研发活动，加上医疗保健基础设施的改善，进一步推动了市场成长。亚太地区的策略进步和投资使其成为反义和 RNAi 治疗产业扩张的重要贡献者。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 神经退化性疾病和遗传性疾病的盛行率不断增加
    • 基因表现和传递技术相关研究的投资不断增加
    • RNAi 和反义疗法的监管批准数量增长
    • 人们对基于 RNA 的疗法的认识不断提高
  • 产业陷阱与挑战
    • 临床研究需要大量投资
    • 基于 RNA 的疗法成本高昂
• 成长潜力分析
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按技术划分，2021 - 2032 年

• 主要趋势
• RNA干扰
• 反义RNA

第 6 章：市场估计与预测：按给药途径，2021 - 2032 年

• 主要趋势
• 静脉注射
• 鞘内注射
• 皮下注射
• 其他给药途径

第 7 章：市场估计与预测：按应用分类，2021 - 2032

• 主要趋势
• 心臟代谢和肾臟疾病
• 癌症
• 神经退化性疾病
• 遗传性疾病
• 传染病
• 眼科疾病
• 皮肤病
• 其他应用

第 8 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• Alnylam Pharmaceuticals, Inc.
• Arbutus Biopharma
• Arrowhead Pharmaceuticals, Inc.
• Benitec Biopharma Inc.
• BioNTech SE.
• CRISPR Therapeutics
• GlaxoSmithKline plc
• Ionis Pharmaceuticals, Inc.
• Novartis AG
• OliX Pharmaceuticals, Inc.
• Orna Therapeutics, Inc.
• Percheron Therapeutics Ltd.
• Sanofi
• Sarepta Therapeutics, Inc.
• Silence Therapeutics

Global Antisense and RNAi Therapeutics Market will grow at an 18.2% CAGR during 2024 and 2032, propelled by growing research and development coupled with the expansion of clinical trials. Continuous R&D efforts lead to the discovery of innovative therapies and improvements in delivery mechanisms, enhancing the efficacy of antisense and RNAi treatments. Moreover, the expansion of clinical trials validates these advancements and supports their progression through regulatory pathways. This synergy of ongoing research and robust trial activities fosters market growth, increasing the availability and adoption of these advanced therapeutic solutions.

For instance, in August 2023, Sirnaomics Ltd. successfully completed Phase I of its STP707 RNAi therapeutic study, showing positive results in treating multiple solid tumors in late-stage cancer patients unresponsive to previous treatments. This development highlights the potential of RNAi therapies to address complex oncology cases where other treatments have failed, enhancing the appeal of RNAi-based solutions. It may drive increased investment and research in RNAi therapeutics, expand market opportunities, and validate the effectiveness of RNAi technology in cancer treatment.

The antisense and RNAi therapeutics industry is divided based on technology, route of administration, application, and region.

The subcutaneous injections segment will experience a marked upturn through 2032, driven by its practicality and patient-friendly nature. Subcutaneous injections allow for the administration of therapeutics with relatively simple techniques and minimal discomfort, making them ideal for long-term treatments. This route of delivery is also well-suited for therapies requiring frequent dosing or self-administration, enhancing patient adherence. As antisense and RNAi therapeutics advance, the convenience and efficiency of subcutaneous injections position them as the preferred method for widespread clinical use.

The cancer segment will witness a considerable surge between 2024 and 2032, attributed to the increasing demand for targeted treatments in oncology. Antisense and RNAi technologies offer precise mechanisms for silencing genes associated with cancer progression, providing innovative treatment approaches. As the understanding of cancer genomics advances, these therapies are becoming crucial for developing personalized medicine strategies. The significant potential for improving patient outcomes and overcoming drug resistance in cancer treatment drives the dominance of this segment in the market.

Asia Pacific antisense and RNAi therapeutics market share will register a noteworthy CAGR from 2024 to 2032, owing to the country's rapidly growing healthcare sector and increasing investment in biotechnology. The region's expanding patient population, rising prevalence of chronic diseases, and supportive government policies drive the demand for advanced therapeutic solutions. Additionally, substantial research and development activities, coupled with improvements in healthcare infrastructure, further boost market growth. Asia Pacific's strategic advancements and investments make it a vital contributor to the expansion of the antisense and RNAi therapeutics industry.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of neurodegenerative and genetic disorders
    • 3.2.1.2 Growing investments in research related to gene expression and delivery technologies
    • 3.2.1.3 Growth in regulatory approvals for RNAi and antisense therapeutics
    • 3.2.1.4 Rising awareness towards RNA-based therapeutics
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Requirement for significant investments in clinical studies
    • 3.2.2.2 High cost of RNA-based therapies
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 RNA interference
• 5.3 Antisense RNA

Chapter 6 Market Estimates and Forecast, By Route of administration, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Intravenous injections
• 6.3 Intrathecal injections
• 6.4 Subcutaneous injections
• 6.5 Other routes of administration

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Cardiometabolic & renal disorders
• 7.3 Cancer
• 7.4 Neurodegenerative disorders
• 7.5 Genetic disorders
• 7.6 Infectious diseases
• 7.7 Ophthalmic diseases
• 7.8 Skin diseases
• 7.9 Other applications

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Alnylam Pharmaceuticals, Inc.
• 9.2 Arbutus Biopharma
• 9.3 Arrowhead Pharmaceuticals, Inc.
• 9.4 Benitec Biopharma Inc.
• 9.5 BioNTech SE.
• 9.6 CRISPR Therapeutics
• 9.7 GlaxoSmithKline plc
• 9.8 Ionis Pharmaceuticals, Inc.
• 9.9 Novartis AG
• 9.10 OliX Pharmaceuticals, Inc.
• 9.11 Orna Therapeutics, Inc.
• 9.12 Percheron Therapeutics Ltd.
• 9.13 Sanofi
• 9.14 Sarepta Therapeutics, Inc.
• 9.15 Silence Therapeutics